TY - JOUR
T1 - Update on research and clinical translation on specific clinical areas from biology to bedside
T2 - Unpacking the mysteries of juvenile idiopathic arthritis pathogenesis
AU - van Loosdregt, Jorg
AU - van Wijk, Femke
AU - Prakken, Berent
AU - Vastert, Bas
N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - In the past decades, we have gained important insights into the mechanisms of disease and therapy underlying chronic inflammation in juvenile idiopathic arthritis (JIA). These insights have resulted in several game-changing therapeutic modalities for many patients. However, additional progress still has to be made with regard to efficacy, cost reduction, minimization of side effects, and dose-tapering and stop strategies of maintenance drugs. Moreover, to really transform the current therapeutic strategies into personalized medicine, we need validated biomarkers to translate increased insights into clinical practice. In this article, we describe recent developments in JIA research and outline how clinical innovations need to go hand in hand with basic discoveries to really effect care for patients. Facilitating the transition from bench to bedside is crucial for addressing the major current challenges in JIA management. When successful, it will set new standards for a safe, targeted, and personalized medicine in JIA.
AB - In the past decades, we have gained important insights into the mechanisms of disease and therapy underlying chronic inflammation in juvenile idiopathic arthritis (JIA). These insights have resulted in several game-changing therapeutic modalities for many patients. However, additional progress still has to be made with regard to efficacy, cost reduction, minimization of side effects, and dose-tapering and stop strategies of maintenance drugs. Moreover, to really transform the current therapeutic strategies into personalized medicine, we need validated biomarkers to translate increased insights into clinical practice. In this article, we describe recent developments in JIA research and outline how clinical innovations need to go hand in hand with basic discoveries to really effect care for patients. Facilitating the transition from bench to bedside is crucial for addressing the major current challenges in JIA management. When successful, it will set new standards for a safe, targeted, and personalized medicine in JIA.
KW - Arthritis, Juvenile/drug therapy
KW - Biology
KW - Biomarkers
KW - Child
KW - Humans
KW - Point-of-Care Systems
KW - Precision Medicine
KW - Translational Research, Biomedical
UR - http://www.scopus.com/inward/record.url?scp=85047062931&partnerID=8YFLogxK
U2 - 10.1016/j.berh.2018.02.003
DO - 10.1016/j.berh.2018.02.003
M3 - Article
C2 - 29773267
AN - SCOPUS:85047062931
SN - 1521-6942
VL - 31
SP - 460
EP - 475
JO - Best Practice and Research: Clinical Rheumatology
JF - Best Practice and Research: Clinical Rheumatology
IS - 4
ER -